Sulforaphane-Loaded Ultradeformable Vesicles as A Potential Natural Nanomedicine for the Treatment of Skin Cancer Diseases.
anticancer activity
ethosomes®
human stratum corneum
percutaneous permeation
sulphoraphane
transfersomes®
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
19 Dec 2019
19 Dec 2019
Historique:
received:
13
11
2019
revised:
09
12
2019
accepted:
17
12
2019
entrez:
22
12
2019
pubmed:
22
12
2019
medline:
22
12
2019
Statut:
epublish
Résumé
Sulforaphane is a multi-action drug and its anticancer activity is the reason for the continuous growth of attention being paid to this drug. Sulforaphane shows an in vitro antiproliferative activity against melanoma and other skin cancer diseases. Unfortunately, this natural compound cannot be applied in free form on the skin due to its poor percutaneous permeation determined by its physico-chemical characteristics. The aim of this investigation was to evaluate ethosomes
Identifiants
pubmed: 31861672
pii: pharmaceutics12010006
doi: 10.3390/pharmaceutics12010006
pmc: PMC7023209
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Nutr Biochem. 2017 Apr;42:72-83
pubmed: 28131897
Biochim Biophys Acta. 1998 Jan 19;1368(2):201-15
pubmed: 9459598
Int J Pharm. 2004 May 4;275(1-2):13-7
pubmed: 15081134
Eur J Nutr. 2018 Oct;57(7):2547-2569
pubmed: 28864908
AAPS PharmSciTech. 2017 Aug;18(6):2131-2140
pubmed: 28028793
Toxicol Lett. 2010 Feb 15;192(3):278-85
pubmed: 19913604
J Invest Dermatol. 1992 Jun;98(6):856-63
pubmed: 1593149
Planta Med. 2017 Mar;83(5):482-491
pubmed: 27542175
Neurobiol Aging. 2016 Feb;38:1-10
pubmed: 26827637
PLoS One. 2014 Mar 25;9(3):e92980
pubmed: 24667842
Nanomaterials (Basel). 2016 May 18;6(5):
pubmed: 28335220
PLoS One. 2015 Sep 24;10(9):e0138771
pubmed: 26402917
Biomed Microdevices. 2012 Feb;14(1):119-30
pubmed: 21960035
Colloids Surf B Biointerfaces. 2009 Aug 1;72(1):155-60
pubmed: 19376689
J Control Release. 2000 Apr 3;65(3):403-18
pubmed: 10699298
J Cancer. 2017 Aug 2;8(13):2456-2470
pubmed: 28900483
Colloids Surf B Biointerfaces. 2017 Feb 1;150:408-416
pubmed: 27829536
Mol Carcinog. 2016 Dec;55(12):2024-2036
pubmed: 26693692
J Control Release. 2004 Feb 10;94(2-3):365-79
pubmed: 14744487
Biomed Chromatogr. 2010 Apr;24(4):387-92
pubmed: 19650149
Front Pharmacol. 2015 Sep 30;6:219
pubmed: 26483690
Am J Chin Med. 2016;44(6):1289-1310
pubmed: 27627923
Food Chem Toxicol. 2018 May;115:185-197
pubmed: 29548851
Int J Pharm. 2011 Jun 15;411(1-2):223-31
pubmed: 21458550
J Neurochem. 2015 Dec;135(5):932-42
pubmed: 26365487
Drug Dev Ind Pharm. 2014 Apr;40(4):494-502
pubmed: 23611476
Cardiovasc Ther. 2017 Oct;35(5):
pubmed: 28636290
Nutr Cancer. 2017 Oct;69(7):969-978
pubmed: 28872903
J Control Release. 2005 Aug 18;106(1-2):99-110
pubmed: 15935505
Oncol Rep. 2007 Nov;18(5):1263-8
pubmed: 17914583
Oxid Med Cell Longev. 2017;2017:3839756
pubmed: 28386307
Curr Drug Targets. 2015;16(14):1612-22
pubmed: 26601721
J Drug Target. 2001;9(1):49-59
pubmed: 11378523
Eur J Pharm Biopharm. 2012 May;81(1):102-12
pubmed: 22414731
Expert Opin Drug Deliv. 2008 Jul;5(7):737-55
pubmed: 18590459